Neuphoria Therapeutics Inc. Payments of Stock Issuance Costs
Neuphoria Therapeutics Inc. (NEUP) reported Payments of Stock Issuance Costs of $600.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-09-18
- Neuphoria Therapeutics Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $500.00K, a 12.63% decline year-over-year.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $100.00K, a 56.09% decline year-over-year.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for fiscal 2026 was $600.00K, a 500.00% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for fiscal 2025 was $100.00K, a 92.31% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for fiscal 2024 was $1.30M, a 18.18% increase from fiscal 2023.
- Neuphoria Therapeutics Inc. payments of stock issuance costs for fiscal 2023 was $1.10M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $0.00 derived: sum of 2 quarters · filed 2026-09-18 | $500.00K derived: sum of 3 quarters · filed 2026-09-18 | $600.00K 10-K · filed 2026-09-18 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $500.00K derived: sum of 2 quarters · filed 2026-05-15 | $600.00K 10-Q · filed 2026-05-15 | $300.00K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $500.00K 10-Q · filed 2026-05-15 | $600.00K 10-Q · filed 2026-02-17 | $300.00K derived: sum of 3 quarters · filed 2026-09-18 | $400.00K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $100.00K 10-Q · filed 2026-05-15 | -$200.00K derived: sum of 2 quarters · filed 2026-09-18 | -$100.00K derived: sum of 3 quarters · filed 2026-09-18 | $472.25K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$200.00K derived: sum of 2 quarters · filed 2026-09-18 | $372.25K derived: sum of 3 quarters · filed 2026-09-18 | $100.00K 10-K · filed 2026-09-18 |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-15 | $672.25K derived: sum of 2 quarters · filed 2026-05-15 | $400.00K 10-Q · filed 2026-05-15 | $1.30M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $572.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $800.00K 10-Q · filed 2025-02-14 | $1.20M derived: sum of 3 quarters · filed 2025-09-29 | $1.30M derived: sum of 4 quarters · filed 2025-09-29 |
| 2024-09-30 | $227.75K 10-Q · filed 2024-11-14 | $627.75K derived: sum of 2 quarters · filed 2025-09-29 | $727.75K derived: sum of 3 quarters · filed 2025-09-29 | $1.03M derived: sum of 4 quarters · filed 2025-09-29 |
| 2024-06-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $500.00K derived: sum of 2 quarters · filed 2025-09-29 | $800.00K derived: sum of 3 quarters · filed 2025-09-29 | $1.30M 10-K · filed 2025-09-29 |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-20 | $400.00K derived: sum of 2 quarters · filed 2025-05-20 | $900.00K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $300.00K 10-Q · filed 2025-05-20 | $800.00K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $500.00K 10-Q · filed 2025-05-20 | |||
| 2023-06-30 | $1.10M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |